Antares Pharma to Present at the Jefferies 2018 Healthcare Conference
May 29 2018 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at
9:00 a.m. Eastern Time.
A live webcast of the presentation will be
available under the “For Investors” section of the Antares website,
www.antarespharma.com. A replay of the webcast will also be
archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma, Inc. is a specialty
pharmaceutical company focused on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injection
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
advanced stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva) and AMAG
Pharmaceuticals, Inc. Antares Pharma’s proprietary products
include OTREXUP® (methotrexate) injection for subcutaneous use and
Sumatriptan Injection USP, which is distributed by Teva. The
Company has developed an investigational new drug for testosterone
replacement therapy called XYOSTED™, currently under active review
at the FDA with a PDUFA date of September 29, 2018.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: successful completion
of the transaction with Ferring International Center, S.A. and
satisfaction of the various conditions in the Ferring asset
purchase agreement and payment of the full purchase price; the
Company’s ability to resolve the deficiencies identified by the FDA
in the Complete Response Letter for XYOSTED™, FDA
approval of the Company’s NDA for
XYOSTED™ and future market acceptance and
revenue for XYOSTED™; the future market acceptance
and revenue from Makena® subcutaneous auto injector; Teva’s ability
to successfully commercialize VIBEX® Sumatriptan Injection USP and
the amount of revenue from the same; continued growth of
prescriptions and sales of OTREXUP®; the timing and results
of the Company’s or its partners’ research projects or clinical
trials of product candidates in development; actions by the FDA or
other regulatory agencies with respect to the Company’s
products or product candidates of its partners; continued growth in
product, development, licensing and royalty revenue; the Company’s
ability to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not
to place undue reliance on the forward-looking statements contained
in this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:
Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024